Senhwa Biosciences inks up to $16M funding deal with GEM to boost AI drug discovery

Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development. According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU)…